Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34 million) investment from the British Business Bank - the Bank's largest investment in a ...
Julie Coletti "is a highly accomplished legal and business leader with deep experience across the life sciences and medical ...
Just over two decades ago, reading the complete human genome was considered one of the most ambitious scientific projects ever attempted. The international Human Genome Project took nearly 13 years ...
Aardaia will use the new funding to expand its crop breeding platform and accelerate the development of the aardaker, a ...
Illumina, Inc. (NASDAQ:ILMN) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 26, Bernstein SocGen analyst Eve Burstein resumed coverage of Illumina, Inc.
When Roche previewed the Axelios technology in February, a Jefferies analyst called the next-generation sequencing platform the “greatest credible competitive threat in years.” ...
Caris Life Sciences ® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
Highly sensitive next-generation sequencing-based MRD testing will identify eligible patients with T-cell malignancies ...
Liquid biopsy's promise depends on what happens before the data: reliable collection, preservation, and preparation. IRVINE, Calif., June 30, 2026 /PRNewswire/ -- Zymo Research Corp., a global life ...
We spoke to David Klenerman, co-developer of sequencing by synthesis, to find out how his work heralded the next generation ...
By Bhanvi Satija and Marleen Kaesebier LONDON/ZURICH, June 29 (Reuters) - Roche launched its next-generation gene sequencing ...
Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of the gene sequencing specialist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results